newsfilter
← Latest News
PR Newswire·

CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London

CTSO
  • CytoSorbents Corporation CEO Dr. Phillip Chan & CFO Mr. Peter Mariani will attend one-on-one investor meetings at the Jefferies Global Healthcare Conference in London from November 16-18, 2026.
  • Investors can schedule meetings through the conference website or contact the investor relations team at ir@cytosorbents.com.
  • The Jefferies Global Healthcare Conference is a 17th annual event organized by Jefferies, featuring C-suite executives & investors across the healthcare sector.
  • CytoSorbents utilizes biocompatible polymer beads to remove toxic substances from blood via pore capture & surface adsorption for use in intensive care & cardiac surgery.
  • Key applications include removing blood thinners during cardiothoracic surgery & eliminating inflammatory agents in critical illnesses like sepsis, trauma, & organ failure.
  • The lead product CytoSorb® is approved in the EU & distributed in over 70 countries with more than 300,000 devices used cumulatively.
  • CytoSorb® holds CE mark extensions for bilirubin & myoglobin removal, plus ticagrelor & rivaroxaban removal, & received FDA Emergency Use Authorization for adult COVID-19 patients in the U.S.
  • CytoSorb® is not yet approved or cleared in the United States, while the investigational DrugSorb®-ATR system is being developed for the U.S. & Canada to reduce perioperative bleeding.
  • DrugSorb®-ATR has received two FDA Breakthrough Device Designations for removing ticagrelor & direct oral anticoagulants (DOACs) during cardiothoracic surgery.
  • The Company expects to achieve cash-flow break-even in the second half of 2026 & is pursuing FDA & Health Canada marketing authorization for DrugSorb®-ATR.
  • CytoSorbents holds numerous patents & trademarks for products including CytoSorb-XL™, HemoDefend-RBC™, & VetResQ®, among others.
  • The press release includes forward-looking statements regarding future targets & regulatory outcomes, noting risks such as restructuring in Germany & financing needs.
Company
Cytosorbents Corp
Keywords
Cytosorbents Corp